Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894083 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
A Phase 2 study of Oropharyngeal Cancer and Squamous Cell Carcinoma of the Oropharynx, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05894083 is a Phase 2 study of Oropharyngeal Cancer and Squamous Cell Carcinoma of the Oropharynx that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 150 participants, below the 184-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05894083, a Phase 2 study of Oropharyngeal Cancer and Squamous Cell Carcinoma of the Oropharynx, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Single center, non-randomized Phase II study enrolling Stage I-II p16+ oropharyngeal cancer patients to one of two de-escalation treatment paradigms: (1) receive surgery followed by observation or risk-adjusted adjuvant radiation (+/-chemo), or (2) individualized adaptive definitive chemoradiation (CRT).
Conditions Studied
Interventions
- OTHER Observation
- PROCEDURE Surgery
- COMBINATION_PRODUCT Chemoradiation
- RADIATION Post-operative radiation
Study Locations (1)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-04-27 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05894083
The ClinicalTrials.gov registry entry for NCT05894083 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (18% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Observation is the first listed.
NCT05894083 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05894083 about?
NCT05894083 is a clinical study titled "A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)". Single center, non-randomized Phase II study enrolling Stage I-II p16+ oropharyngeal cancer patients to one of two de-escalation treatment paradigms: (1) receive surgery followed by observation or risk-adjusted adjuvant radiation (+/-chemo), or (2) individualized adaptive definitive chemoradiation (...
What is the current status of trial NCT05894083?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2023-04-27. Estimated completion is 2030-12.
What conditions does trial NCT05894083 study?
This clinical trial studies the following conditions: Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx.
What interventions are being tested in trial NCT05894083?
The interventions under investigation include: Observation (OTHER), Surgery (PROCEDURE), Chemoradiation (COMBINATION_PRODUCT), Post-operative radiation (RADIATION).
Who is sponsoring clinical trial NCT05894083?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05894083 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
RECRUITING · Phase 2
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
-
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
RECRUITING · Phase 2
-
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
RECRUITING · Phase 2
-
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Oropharyngeal Cancer
All registered trials for this condition
Squamous Cell Carcinoma of the Oropharynx
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.